Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter

Maideen, Naina Mohamed Pakkir; Manavalan, Gobinath; Kumar, B. Krishna

doi:10.1177/2042018818767220

Cited by 20 publications

(12 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 Patients with type 2 diabetes are usually treated with oral antidiabetic drugs such as metformin, sulfonylureas, meglitinides, thiazolidinediones (TZDs), dipeptidyl peptidase 4 (DPP4) inhibitors and SGLT2 inhibitors. 4 5 …”

Section: Introductionmentioning

confidence: 99%

Antidiabetic Activity of Nigella Sativa (Black Seeds) and Its Active Constituent (Thymoquinone): A Review of Human and Experimental Animal Studies

Maideen

2021

Chonnam Med J

View full text Add to dashboard Cite

The use of herbal medicine to manage chronic conditions including diabetes has become a recent global trend. Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia. The present review is aimed to analyze the antidiabetic activity of N. sativa as many type 2 diabetic patients use it as a complementary therapy along with their modern allopathic medications or as an alternative therapy. The literature was reviewed in databases like Medline/PubMed Central/PubMed, Google Scholar, Science Direct, EBSCO, Scopus, Web of science, EMBASE, Directory of open access journals (DOAJ), and reference lists to identify relevant articles supporting the use of N. sativa in diabetes management. Numerous clinical and animal studies have demonstrated the antidiabetic efficacy of black seeds ( N. sativa ) and its major bioactive constituent thymoquinone. Based on these findings patients with diabetes may use N. sativa as an adjuvant therapy, which may help to reduce the dose and incidence of adverse effects of modern antidiabetic medicines.

show abstract

Section: Introductionmentioning

confidence: 99%

Antidiabetic Activity of Nigella Sativa (Black Seeds) and Its Active Constituent (Thymoquinone): A Review of Human and Experimental Animal Studies

Maideen

2021

Chonnam Med J

View full text Add to dashboard Cite

show abstract

“…11 Meglitinide analogues (repaglinide and nateglinide) also are insulin secretagogues, but are shorter and faster acting. 12 DPP-4 inhibitors prevent the breakdown of glucagon like peptide-1 (GLP-1) secreted by intestinal tract, which inhibits glucagon release, gluconeogenesis and gastric emptying gets delayed. 13 There has been a better understanding of kidney's role in glucose homeostasis leading to development of SGLT-2 inhibitors.…”

Section: Introductionmentioning

confidence: 99%

Need of the hour: pharmacovigilance study of SGLT-2 inhibitors

Pradhan¹,

Tejus²,

Koley³

et al. 2019

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Diabetes mellitus represents a global pandemic. Various pharmacotherapy and non-pharmacotherapy measures are advocated for its control. The latest in the pharmacotherapy are Sodium Glucose Transporter -2 (SGLT-2) inhibitors, widely used. Many studies suggest adverse effects related to SGLT-2 inhibitors, evidence still not conclusive and few data from India. Hence this study was planned.Methods: Cross-sectional study over a period of 02 months, recorded demographic details and history of various adverse drug reactions reported with the use of SGLT-2 inhibitors.Results: Majority of the study participants were females (58%) and belonged to the age group of 40-70 yrs. Urinary tract infections (UTI) and genital infections was more seen in the users of dapagliflozin, followed by empagliflozin and canagliflozin.Conclusions: SGLT-2 Inhibitors offer a unique therapeutic approach to the management of Diabetes Mellitus. Further evaluation of the safety profile and the risk-benefit analysis is the need of the hour.

show abstract

“…5 Modification of effects of one drug by other drug(s), supplements, food, smoking or alcohol consumption, is termed as Drug interaction. 6 And the drug interaction resulting in elevated risk of adverse effects or decreased therapeutic efficacy is termed Adverse Drug Interaction. 7 GLP-1 agonists may slow down the absorption of certain orally administered medications through delayed gastric emptying.…”

Section: Introductionmentioning

confidence: 99%

Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists

Maideen¹

2019

JAPLR

View full text Add to dashboard Cite

Glucagon-like peptide-1 receptor agonists are incretin mimetics and they help to manage the blood glucose of patients with type 2 diabetes mellitus. The gastric emptying is delayed by the administration of Glucagon-like peptide-1 receptor agonists and hence the absorption of orally administered medications such as Acetaminophen, Digoxin, Warfarin, Oral contraceptive pills, Metformin, Statins, Angiotensin Converting Enzyme Inhibitors and Griseofulvin delayed by their concomitant use. It has been observed that the pharmacokinetics of all these drugs did not get altered by the concurrent administration of Glucagon-like peptide-1 receptor agonists. Moreover, the delay in absorption of interacting drugs could be avoided by taking 1 hour before the administration of Glucagon-like peptide-1 receptor agonists.

show abstract

Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter

Cited by 20 publications

References 98 publications

Antidiabetic Activity of Nigella Sativa (Black Seeds) and Its Active Constituent (Thymoquinone): A Review of Human and Experimental Animal Studies

Antidiabetic Activity of Nigella Sativa (Black Seeds) and Its Active Constituent (Thymoquinone): A Review of Human and Experimental Animal Studies

Need of the hour: pharmacovigilance study of SGLT-2 inhibitors

Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists

Contact Info

Product

Resources

About